Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT04951492
Phase
PHASE2
Status
Terminated

Conditions

  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Nov 9, 2022
Status verified
Dec 2024
Primary completion
Oct 15, 2023
Completion
Oct 15, 2023

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (Olaparib)
    Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Lowest On-treatment Prostate Specific Antigen (PSA) [ Time Frame: At least 12 weeks of olaparib treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109-

Find similar trials in Seattle, WA

By research site
Fred Hutch/University of Washington Cancer Consortium· Seattle, WA

Related Studies